CARM Key Statistics, Chart & Performance
The current stock price of CARM is 0.1539 USD. In the past month the price decreased by -58.86%. In the past year, price decreased by -83.48%.
CARM Technical Analysis
CARM Financial Highlights
Over the last trailing twelve months CARM reported a non-GAAP Earnings per Share(EPS) of -1.18. The EPS increased by 33.71% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -985.18% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
CARM Forecast & Estimates
8 analysts have analysed CARM and the average price target is 1.02 USD. This implies a price increase of 562.77% is expected in the next year compared to the current price of 0.1539.
For the next year, analysts expect an EPS growth of 45.16% and a revenue growth -100% for CARM
CARM Ownership
CARM Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.36 | 390.15B | ||
| AMGN | AMGEN INC | 14.83 | 174.63B | ||
| GILD | GILEAD SCIENCES INC | 14.87 | 151.07B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.19 | 115.36B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.86 | 79.76B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 725.41 | 48.88B | ||
| INSM | INSMED INC | N/A | 34.92B | ||
| NTRA | NATERA INC | N/A | 32.83B | ||
| BIIB | BIOGEN INC | 10.65 | 26.16B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 23.19B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.07 | 20.53B | ||
| INCY | INCYTE CORP | 16.11 | 20.31B |
Related stock screener links
About CARM
Company Profile
Carisma Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery and development of immunotherapies. The company is headquartered in Philadelphia, Pennsylvania and currently employs 46 full-time employees. The company went IPO on 2014-02-06. The firm seeks to apply the ability to engineer macrophages and monocytes, either in vivo or ex vivo. Its proprietary chimeric antigen receptor macrophages(CAR-M) platform uses CARs to redirect macrophages or monocytes against specific tumor associated antigens with the goal of targeted antitumor immunity. The company is developing a pipeline of product candidates which includes CT-1119, In Vivo CAR-Macrophage: GPC3+ Solid Tumors, In Vivo CAR-Macrophage: Oncology Targets, and CT-2401 (Liver Fibrosis). CT-2401 is a product candidate in development for liver fibrosis, and CT-1119 is a mesothelin-targeted CAR-Monocyte that is designed to treat patients with advanced mesothelin-positive solid tumors, including pancreatic cancer, ovarian cancer, lung cancer, mesothelioma, and others.
Company Info
CARISMA THERAPEUTICS INC
3675 Market Street, Suite 401
PHILADELPHIA PENNSYLVANIA US
Employees: 46
Phone: 12674916422
CARISMA THERAPEUTICS INC / CARM FAQ
Can you describe the business of CARISMA THERAPEUTICS INC?
Carisma Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery and development of immunotherapies. The company is headquartered in Philadelphia, Pennsylvania and currently employs 46 full-time employees. The company went IPO on 2014-02-06. The firm seeks to apply the ability to engineer macrophages and monocytes, either in vivo or ex vivo. Its proprietary chimeric antigen receptor macrophages(CAR-M) platform uses CARs to redirect macrophages or monocytes against specific tumor associated antigens with the goal of targeted antitumor immunity. The company is developing a pipeline of product candidates which includes CT-1119, In Vivo CAR-Macrophage: GPC3+ Solid Tumors, In Vivo CAR-Macrophage: Oncology Targets, and CT-2401 (Liver Fibrosis). CT-2401 is a product candidate in development for liver fibrosis, and CT-1119 is a mesothelin-targeted CAR-Monocyte that is designed to treat patients with advanced mesothelin-positive solid tumors, including pancreatic cancer, ovarian cancer, lung cancer, mesothelioma, and others.
What is the stock price of CARISMA THERAPEUTICS INC today?
The current stock price of CARM is 0.1539 USD. The price decreased by -43.81% in the last trading session.
What is the dividend status of CARISMA THERAPEUTICS INC?
CARM does not pay a dividend.
What is the ChartMill technical and fundamental rating of CARM stock?
CARM has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
Can you provide the number of employees for CARISMA THERAPEUTICS INC?
CARISMA THERAPEUTICS INC (CARM) currently has 46 employees.
Can you provide the market cap for CARISMA THERAPEUTICS INC?
CARISMA THERAPEUTICS INC (CARM) has a market capitalization of 6.43M USD. This makes CARM a Nano Cap stock.
What is the Short Interest ratio of CARISMA THERAPEUTICS INC (CARM) stock?
The outstanding short interest for CARISMA THERAPEUTICS INC (CARM) is 1.28% of its float.